S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
UN takes no immediate action at emergency meeting on Guyana-Venezuela dispute over oil-rich region
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
UN takes no immediate action at emergency meeting on Guyana-Venezuela dispute over oil-rich region
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
UN takes no immediate action at emergency meeting on Guyana-Venezuela dispute over oil-rich region
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
UN takes no immediate action at emergency meeting on Guyana-Venezuela dispute over oil-rich region

Pacific Biosciences of California (PACB) Stock Forecast & Price Target

$8.59
+0.21 (+2.51%)
(As of 12/8/2023 ET)
Compare
Today's Range
$8.18
▼
$8.67
50-Day Range
$5.97
▼
$9.03
52-Week Range
$5.74
▼
$14.55
Volume
2.91 million shs
Average Volume
4.38 million shs
Market Capitalization
$2.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.80
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Pacific Biosciences of California Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 11 Analyst Ratings

Analysts' Consensus Price Target

$11.80
37.37% Upside
High Forecast$17.00
Average Forecast$11.80
Low Forecast$8.00
TypeCurrent Forecast
12/9/22 to 12/9/23		1 Month Ago
11/9/22 to 11/9/23		3 Months Ago
9/10/22 to 9/10/23		1 Year Ago
12/9/21 to 12/9/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.80$12.10$13.89$13.00
Predicted Upside37.37% Upside39.98% Upside26.35% Upside59.41% Upside
Get Pacific Biosciences of California Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.


PACB Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PACB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pacific Biosciences of California Stock vs. The Competition

TypePacific Biosciences of CaliforniaMedical CompaniesS&P 500
Consensus Rating Score
2.73
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside37.37% Upside735.83% Upside3,819.09% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/17/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$13.00 ➝ $10.00+31.75%
11/6/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$9.00 ➝ $8.00+16.62%
10/31/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$17.00 ➝ $15.00+136.22%
10/31/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		R. Osborn
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeNeutral ➝ Overweight$14.00 ➝ $11.00+66.16%
10/24/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight ➝ Equal Weight$13.00 ➝ $10.00+37.74%
9/29/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $9.00+7.66%
9/28/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$11.00+31.58%
6/30/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$17.00+29.57%
6/7/2023KGI Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform
3/31/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeMarket Perform ➝ Outperform$13.00 ➝ $15.00+53.69%
1/4/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageSector Outperform$12.00+45.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:51 PM ET.












PACB Price Target - Frequently Asked Questions

What is Pacific Biosciences of California's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for Pacific Biosciences of California stock is Moderate Buy based on the current 3 hold ratings and 8 buy ratings for PACB. The average twelve-month price prediction for Pacific Biosciences of California is $11.80 with a high price target of $17.00 and a low price target of $8.00. Learn more on PACB's analyst rating history.

Do Wall Street analysts like Pacific Biosciences of California more than its competitors?

Analysts like Pacific Biosciences of California more than other Medical companies. The consensus rating score for Pacific Biosciences of California is 2.73 while the average consensus rating score for medical companies is 2.68. Learn more on how PACB compares to other companies.

Is Pacific Biosciences of California being upgraded by Wall Street analysts?

Over the previous 90 days, Pacific Biosciences of California's stock had 2 upgrades by analysts.

Does Pacific Biosciences of California's stock price have much upside?

According to analysts, Pacific Biosciences of California's stock has a predicted upside of 42.94% based on their 12-month stock forecasts.

What analysts cover Pacific Biosciences of California?

Pacific Biosciences of California has been rated by Barclays, Canaccord Genuity Group, Cantor Fitzgerald, Morgan Stanley, Piper Sandler, Sanford C. Bernstein, and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:PACB) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -